Chinese biopharma firm JW Therapeutics nets $100m in Series B round

Chinese biopharma firm JW Therapeutics nets $100m in Series B round

A technician handles a sample at a laboratory. Photographer: Anthony Kwan/Bloomberg

10 June, 2020

CPE JW Therapeutics Mirae Asset

Printed by Unregistered user on Tue, 22 Jul 2025 14:47:46 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Chinese biopharma firm MabPlex nets $71m in Series B round

Biopharma startup Everest Medicines closes $300m Series C round led by Hillhouse, others

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation